Skip to main content
Log in

Comparative Risk for Harms of Second Generation Antidepressants

A Systematic Review and Meta Analysis

  • Orginal Research Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Background: Evidence indicates that only minor differences in efficacy exist among second-generation antidepressants for the treatment of major depressive disorder (MDD). However, a comprehensive assessment of both benefits and harms is crucial to evaluate the net benefit.

Objective: To review systematically the comparative harms of second-generation antidepressants for the treatment of MDD in adults by including both experimental and observational evidence.

Data sources: We searched MEDLINE®, EMBASE, PsychLit, The Cochrane Library and the International Pharmaceutical Abstracts from 1980 to April 2007. We manually searched reference lists of pertinent review articles and explored the Center for Drug Evaluation and Research database to identify unpublished research.

Study selection: Eligible study designs were trials and observational studies comparing one drug of interest with another.

Data extraction: Two persons independently reviewed abstracts and full-text articles. One investigator extracted relevant data. A senior reviewer checked data for completeness and accuracy.

Data synthesis: We included 104 experimental and observational studies. If data were sufficient, we conducted meta-analyses of randomized controlled trials on the relative risk of specific adverse events. Findings indicate that the spectrum of adverse events is similar. The frequency of specific adverse events, however, differed across drugs. Venlafaxine was associated with a significantly higher rate of nausea and vomiting than selective serotonin reuptake inhibitors. Compared with other drugs, paroxetine frequently led to more sexual adverse effects and bupropion to fewer such effects; mirtazapine and paroxetine was associated with more weight gain and sertraline with a higher rate of diarrhoea. Overall, however, these differences did not lead to different discontinuation rates. The evidence is insufficient to draw conclusions about rare but severe adverse events.

Conclusions: Adverse event profiles are similar among second-generation antidepressants. However, different frequencies of specific adverse events might be clinically relevant and influence the choice of a treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hansen RA, Gartlehner G, Lohr KN, et al. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 2005; 143(6): 415–26

    PubMed  CAS  Google Scholar 

  2. Williams JW, Mulrow CD, Chiquette E, et al. A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. Ann Intern Med 2000; 132(9): 743–56

    PubMed  CAS  Google Scholar 

  3. Gartlehner G, Hansen R, Thieda P, et al. Comparative effectiveness of second-generation antidepressants in the pharmacologic treatment of adult depression: Comparative Effectiveness Review No. 7-EHC007-EF 2007. Rockville (MD); Agency for Healthcare Research and Quality. [online]. Available from URL: http://www.effectivehealthcare.ahrq.gov/reports/final.cfm [Accessed 2008 Jun 25]

  4. Cipriani A, Barbui C, Brambilla P, et al. Are all antidepressants really the same? The case of fluoxetine: a systematic review. J Clin Psychiatry 2006; 67(6): 850–64

    Article  PubMed  CAS  Google Scholar 

  5. Ioannidis JP, Evans SJ, Gotzsche PC, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 2004; 141(10): 781–8

    PubMed  Google Scholar 

  6. Brunton LL, Lazo JS, Parker KL. Goodman & Gilman’s the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill; 2005

    Google Scholar 

  7. Loke YK, Derry S, Aronson JK. A comparison of three different sources of data in assessing the frequencies of adverse reactions to amiodarone. Br J Clin Pharmacol 2004; 57(5): 616–21

    Article  PubMed  CAS  Google Scholar 

  8. Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med 2001; 20 (3 Suppl.): 21–35

    Article  PubMed  CAS  Google Scholar 

  9. Deeks JJ, Dinnes J, D’Amico R, et al. Evaluating non-randomised intervention studies. Health Technol Assess 2003; 7(27): iii–x, 1-i173

    PubMed  CAS  Google Scholar 

  10. Center for Reviews and Dissemination. Undertaking systematic reviews of research on effectiveness: CRD’s guidance for those carrying out or commissioning reviews. CRD Report Number 4 (2nd ed.) [online]. Available from URL: http://www.york.ac.uk/inst/crd/report4.htm [Accessed 2008 Feb 12]

  11. Gartlehner G, Hansen RA, Nissman D, et al. A simple and valid tool distinguished efficacy from effectiveness studies. J Clin Epidemiol 2006; 60(7): 753–5

    Google Scholar 

  12. Haffmans PM, Timmerman L, Hoogduin CA. Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. The LUCIFER Group. Int Clin Psychopharmacol 1996; 11(3): 157–64

    Article  CAS  Google Scholar 

  13. Rapaport M, Coccaro E, Sheline Y, et al. A comparison of fluvoxamine and fluoxetine in the treatment of major depression. J Clin Psychopharmacol 1996; 16(5): 373–8

    Article  PubMed  CAS  Google Scholar 

  14. Segraves RT, Kavoussi R, Hughes AR, et al. Evaluation of sexual functioning in depressed outpatients: a double-blind comparison of sustained-release bupropion and sertraline treatment. J Clin Psychopharmacol 2000; 20(2): 122–8

    Article  PubMed  CAS  Google Scholar 

  15. Croft H, Settle Jr E, Houser T, et al. A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline. Clin Ther 1999; 21(4): 643–58

    Article  PubMed  CAS  Google Scholar 

  16. Coleman CC, Cunningham LA, Foster VJ, et al. Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment. Ann Clin Psychiatry 1999; 11(4): 205–15

    PubMed  CAS  Google Scholar 

  17. Coleman CC, King BR, Bolden-Watson C, et al. A placebocontrolled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. Clin Ther 2001; 23(7): 1040–58

    Article  PubMed  CAS  Google Scholar 

  18. Feighner JP, Gardner EA, Johnston JA, et al. Double-blind comparison of bupropion and fluoxetine in depressed outpatients. J Clin Psychiatry 1991; 52(8): 329–35

    PubMed  CAS  Google Scholar 

  19. Kavoussi RJ, Segraves RT, Hughes AR, et al. Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. J Clin Psychiatry 1997; 58(12): 532–7

    Article  PubMed  CAS  Google Scholar 

  20. Fava M, Amsterdam JD, Deltito JA, et al. A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression. Ann Clin Psychiatry 1998; 10(4): 145–50

    PubMed  CAS  Google Scholar 

  21. Behnke K, Sogaard J, Martin S, et al. Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study. J Clin Psychopharmacol 2003; 23(4): 358–64

    Article  PubMed  CAS  Google Scholar 

  22. Aberg-Wistedt A, Agren H, Ekselius L, et al. Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy. J Clin Psychopharmacol 2000; 20(6): 645–52

    Article  PubMed  CAS  Google Scholar 

  23. Nemeroff CB, Ninan PT, Ballenger J, et al. Double-blind multicenter comparison of fluvoxamine versus sertraline in the treatment of depressed outpatients. Depression 1995; 3(4): 163–9

    Article  Google Scholar 

  24. Feiger A, Kiev A, Shrivastava RK, et al. Nefazodone versus sertraline in outpatients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry 1996; 57 Suppl. 2: 53–62

    Google Scholar 

  25. Dierick M, Ravizza L, Realini R, et al. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatry 1996; 20(1): 57–71

    Article  PubMed  CAS  Google Scholar 

  26. Tylee A, Beaumont G, Bowden MW, et al. A double-blind, randomized, 12-week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe major depression in general practice. Primary Care Psychiatry 1997; 3(1): 51–8

    Google Scholar 

  27. Rudolph RL, Feiger AD. A double-blind, randomized, placebocontrolled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression. J Affect Disord 1999; 56(2-3): 171–81

    Article  PubMed  CAS  Google Scholar 

  28. Ballus C, Quiros G, De Flores T, et al. The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia. Int Clin Psychopharmacol 2000; 15(1): 43–8

    Article  PubMed  CAS  Google Scholar 

  29. Bielski RJ, Ventura D, Chang CC. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004; 65(9): 1190–6

    Article  PubMed  CAS  Google Scholar 

  30. Montgomery SA, Huusom AK, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004; 50(1): 57–64

    Article  PubMed  CAS  Google Scholar 

  31. Silverstone PH, Ravindran A. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group. J Clin Psychiatry 1999; 60(1): 22–8

    Article  CAS  Google Scholar 

  32. Shelton RC, Haman KL, Rapaport MH, et al. A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder. J Clin Psychiatry 2006; 67(11): 1674–81

    Article  PubMed  CAS  Google Scholar 

  33. McPartlin GM, Reynolds A, Anderson C, et al. A comparison of once-daily venlafaxine XR and paroxetine in depressed outpatients treated in general practice. Primary Care Psychiatry 1998; 4(3): 127–32

    Google Scholar 

  34. Sir A, D’Souza RF, Uguz S, et al. Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. J Clin Psychiatry 2005; 66(10): 1312–20

    Article  PubMed  CAS  Google Scholar 

  35. Alves C, Cachola I, Brandao J. Efficacy and tolerability of venlafaxine and fluoxetine in outpatients with major depression. Primary Care Psychiatry 1999; 5(2): 57–63

    Google Scholar 

  36. Costa e Silva J. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. J Clin Psychiatry 1998; 59(7): 352–7

    Article  PubMed  Google Scholar 

  37. De Nayer A, Geerts S, Ruelens L, et al. Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety. Int J Neuropsychopharmacol 2002; 5(2): 115–20

    Article  PubMed  CAS  Google Scholar 

  38. Mehtonen OP, Sogaard J, Roponen P, et al. Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group. J Clin Psychiatry 2000; 61(2): 95–100

    Article  CAS  Google Scholar 

  39. Nemeroff CB, Thase ME. A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients. J Psychiatr Res 2005; 41(3-4): 351–9

    Article  PubMed  Google Scholar 

  40. Schatzberg A, Roose S. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. Am J Geriatr Psychiatry 2006; 14(4): 361–70

    Article  PubMed  Google Scholar 

  41. Tzanakaki M, Guazzelli M, Nimatoudis I, et al. Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia. Int Clin Psychopharmacol 2000; 15(1): 29–34

    Article  PubMed  CAS  Google Scholar 

  42. Ventura D, Armstrong EP, Skrepnek GH, et al. Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial. Curr Med Res Opin 2007; 23(2): 245–50

    Article  PubMed  CAS  Google Scholar 

  43. Bennie EH, Mullin JM, Martindale JJ. A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression. J Clin Psychiatry 1995; 56(6): 229–37

    PubMed  CAS  Google Scholar 

  44. Ekselius L, von Knorring L, Eberhard G. A double-blind multicenter trial comparing sertraline and citalopram in patients with major depression treated in general practice. Int Clin Psychopharmacol 1997; 12(6): 323–31

    Article  PubMed  CAS  Google Scholar 

  45. Ekselius L, von Knorring L. Effect on sexual function of longterm treatment with selective serotonin reuptake inhibitors in depressed patients treated in primary care. J Clin Psychopharmacol 2001; 21(2): 154–60

    Article  PubMed  CAS  Google Scholar 

  46. Fava M, Rosenbaum JF, Hoog SL, et al. Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression. J Affect Disord 2000; 59(2): 119–26

    Article  PubMed  CAS  Google Scholar 

  47. Rush AJ, Trivedi MH, Carmody TJ, et al. Response in relation to baseline anxiety levels in major depressive disorder treated with bupropion sustained release or sertraline. Neuropsychopharmacology 2001; 25(1): 131–8

    Article  PubMed  CAS  Google Scholar 

  48. Newhouse PA, Krishnan KR, Doraiswamy PM, et al. A doubleblind comparison of sertraline and fluoxetine in depressed elderly outpatients. J Clin Psychiatry 2000; 61(8): 559–68

    Article  PubMed  CAS  Google Scholar 

  49. Finkel SI, Richter EM, Clary CM, et al. Comparative efficacy of sertraline vs. fluoxetine in patients age 70 or over with major depression. Am J Geriatr Psychiatry 1999; 7(3): 221–7

    PubMed  CAS  Google Scholar 

  50. Sechter D, Troy S, Paternetti S, et al. A double-blind comparison of sertraline and fluoxetine in the treatment of major depressive episode in outpatients. Eur Psychiatry 1999; 14(1): 41–8

    Article  PubMed  CAS  Google Scholar 

  51. Halikas JA. Org 3770 (mirtazapine) versus trazodone: a placebo controlled trial in depressed elderly patients. Hum Psychopharmacol 1995; 10 Suppl. 2: S125–33

    Article  CAS  Google Scholar 

  52. Hong CJ, Hu WH, Chen CC, et al. A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks’ treatment with mirtazapine or fluoxetine in depressed Chinese patients. J Clin Psychiatry 2003; 64(8): 921–6

    Article  PubMed  CAS  Google Scholar 

  53. Wheatley DP, van Moffaert M, Timmerman L, et al. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group. J Clin Psychiatry 1998; 59(6): 306–12

    Article  CAS  Google Scholar 

  54. Guelfi JD, Ansseau M, Timmerman L, et al. Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol 2001; 21(4): 425–31

    Article  PubMed  CAS  Google Scholar 

  55. Versiani M, Moreno R, Ramakers-van Moorsel CJ, et al. Comparison of the effects of mirtazapine and fluoxetine in severely depressed patients. CNS Drugs 2005; 19(2): 137–46

    Article  PubMed  CAS  Google Scholar 

  56. Schatzberg AF, Kremer C, Rodrigues HE, et al. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry 2002; 10(5): 541–50

    PubMed  Google Scholar 

  57. Benkert O, Szegedi A, Kohnen R. Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 2000; 61(9): 656–63

    Article  PubMed  CAS  Google Scholar 

  58. Fava M, Judge R, Hoog SL, et al. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry 2000; 61(11): 863–7

    Article  PubMed  CAS  Google Scholar 

  59. Beasley Jr CM, Dornseif BE, Pultz JA, et al. Fluoxetine versus trazodone: efficacy and activating-sedating effects. J Clin Psychiatry 1991; 52(7): 294–9

    PubMed  Google Scholar 

  60. Cunningham LA, Borison RL, Carman JS, et al. A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol 1994; 14(2): 99–106

    Article  PubMed  CAS  Google Scholar 

  61. Kasper S, Olivieri L, Di Loreto G, et al. A comparative, randomised, double-blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder. Curr Med Res Opin 2005; 21(8): 1139–46

    Article  PubMed  CAS  Google Scholar 

  62. Perry PJ, Garvey MJ, Kelly MW, et al. A comparative trial of fluoxetine versus trazodone in outpatients with major depression. J Clin Psychiatry 1989; 50(8): 290–4

    PubMed  CAS  Google Scholar 

  63. Weisler RH, Johnston JA, Lineberry CG, et al. Comparison of bupropion and trazodone for the treatment of major depression. J Clin Psychopharmacol 1994; 14(3): 170–9

    Article  PubMed  CAS  Google Scholar 

  64. Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002; 63(4): 331–6

    Article  PubMed  CAS  Google Scholar 

  65. Colonna L, Andersen HF, Reines EH. A randomized, doubleblind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. Curr Med Res Opin 2005; 21(10): 1659–68

    Article  PubMed  CAS  Google Scholar 

  66. Lepola UM, Loft H, Reines EH. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003; 18(4): 211–7

    Article  PubMed  Google Scholar 

  67. Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005; 20(3): 131–7

    Article  PubMed  Google Scholar 

  68. FDA Center for Drug Evaluation and Research. Statistical review of NDA 21-323 (escitalopram oxalate) [online]. Available from URL: http://www.fda.gov/cder/foi/nda/2002/21-323.pdf_Lexapro_Statr.pdf. [Accessed: 2007 Jul 25]

  69. Patris M, Bouchard JM, Bougerol T, et al. Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice. Int Clin Psychopharmacol 1996; 11(2): 129–36

    PubMed  CAS  Google Scholar 

  70. Kasper S, de Swart H, Friis Andersen H. Escitalopram in the treatment of depressed elderly patients. Am J Geriatr Psychiatry 2005; 13(10): 884–91

    PubMed  Google Scholar 

  71. Boulenger JP, Huusom AK, Florea I, et al. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr Med Res Opin 2006; 22(7): 1331–41

    Article  PubMed  CAS  Google Scholar 

  72. Baldwin DS, Huusom AK, Maehlum E. Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study. Br J Psychiatry 2006; 189: 264–72

    Article  PubMed  Google Scholar 

  73. Dalery J, Honig A. Fluvoxamine versus fluoxetine in major depressive episode: a double-blind randomised comparison. Hum Psychopharmacol 2003; 18(5): 379–84

    Article  PubMed  CAS  Google Scholar 

  74. Cassano GB, Puca F, Scapicchio PL, et al. Paroxetine and fluoxetine effects on mood and cognitive functions in depressed nondemented elderly patients. J Clin Psychiatry 2002; 63(5): 396–402

    Article  PubMed  CAS  Google Scholar 

  75. Chouinard G, Saxena B, Belanger MC, et al. A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder. J Affect Disord 1999; 54(1-2): 39–48

    Article  PubMed  CAS  Google Scholar 

  76. De Wilde J, Spiers R, Mertens C, et al. A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatr Scand 1993; 87(2): 141–5

    Article  PubMed  Google Scholar 

  77. Gagiano CA. A double blind comparison of paroxetine and fluoxetine in patients with major depression. Br J Clin Res 1993; 4: 145–52

    Google Scholar 

  78. Schone W, Ludwig M. A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression. J Clin Psychopharmacol 1993; 13 (6 Suppl. 2): 34S–9S

    PubMed  CAS  Google Scholar 

  79. Tignol J. A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression. J Clin Psychopharmacol 1993; 13 (6 Suppl. 2): 18S–22S

    Article  PubMed  CAS  Google Scholar 

  80. Fava M, Hoog SL, Judge RA, et al. Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia. J Clin Psychopharmacol 2002; 22(2): 137–47

    Article  PubMed  CAS  Google Scholar 

  81. Kroenke K, West SL, Swindle R, et al. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA 2001; 286(23): 2947–55

    Article  PubMed  CAS  Google Scholar 

  82. Boyer P, Danion JM, Bisserbe JC, et al. Clinical and economic comparison of sertraline and fluoxetine in the treatment of depression: a 6-month double-blind study in a primary-care setting in France. Pharmacoeconomics 1998; 13 (1 Pt 2): 157–69

    Article  PubMed  CAS  Google Scholar 

  83. Van Moffaert M, Bartholome F, Cosyns P, et al. A controlled comparison of sertraline and fluoxetine in acute and continuation treatment of major depression. Hum Psychopharmacol 1995; 10: 393–405

    Article  Google Scholar 

  84. Kiev A, Feiger A. A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients. J Clin Psychiatry 1997; 58(4): 146–52

    Article  PubMed  CAS  Google Scholar 

  85. Rossini D, Serretti A, Franchini L, et al. Sertraline versus fluvoxamine in the treatment of elderly patients with major depression: a double-blind, randomized trial. J Clin Psychopharmacol 2005; 25(5): 471–5

    Article  PubMed  CAS  Google Scholar 

  86. Leinonen E, Skarstein J, Behnke K, et al. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group. Int Clin Psychopharmacol 1999; 14(6): 329–37

    Article  CAS  Google Scholar 

  87. Allard P, Gram L, Timdahl K, et al. Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram. Int J Geriatr Psychiatry 2004; 19(12): 1123–30

    Article  PubMed  Google Scholar 

  88. Nierenberg AA, Greist JH, Mallinckrodt CH, et al. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr Med Res Opin 2007; 23(2): 401–16

    Article  PubMed  CAS  Google Scholar 

  89. Goldstein DJ, Mallinckrodt C, Lu Y, et al. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002; 63(3): 225–31

    Article  PubMed  CAS  Google Scholar 

  90. Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004; 14(6): 457–70

    Article  PubMed  CAS  Google Scholar 

  91. Perahia DG, Wang F, Mallinckrodt CH, et al. Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Psychiatry 2006; 21(6): 367–78

    Article  PubMed  CAS  Google Scholar 

  92. Szegedi A, Muller MJ, Anghelescu I, et al. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry 2003; 64(4): 413–20

    Article  PubMed  CAS  Google Scholar 

  93. Rush AJ, Armitage R, Gillin JC, et al. Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. Biol Psychiatry 1998; 44(1): 3–14

    Article  PubMed  CAS  Google Scholar 

  94. Kennedy SH, Fulton KA, Bagby RM, et al. Sexual function during bupropion or paroxetine treatment of major depressive disorder. Can J Psychiatry 2006; 51(4): 234–42

    PubMed  Google Scholar 

  95. Weihs KL, Settle Jr EC, Batey SR, et al. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry 2000; 61(3): 196–202

    Article  PubMed  CAS  Google Scholar 

  96. Baldwin DS, Hawley CJ, Abed RT, et al. A multicenter doubleblind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. J Clin Psychiatry 1996; 57 Suppl. 2: 46–52

    Google Scholar 

  97. Hicks JA, Argyropoulos SV, Rich AS, et al. Randomised controlled study of sleep after nefazodone or paroxetine treatment in out-patients with depression. Br J Psychiatry 2002; 180: 528–35

    Article  PubMed  CAS  Google Scholar 

  98. Ferguson JM, Shrivastava RK, Stahl SM, et al. Reemergence of sexual dysfunction in patients with major depressive disorder: double-blind comparison of nefazodone and sertraline. J Clin Psychiatry 2001; 62(1): 24–9

    Article  PubMed  CAS  Google Scholar 

  99. Munizza C, Olivieri L, Di Loreto G, et al. A comparative, randomized, double-blind study of trazodone prolonged-release and sertraline in the treatment of major depressive disorder. Curr Med Res Opin 2006; 22(9): 1703–13

    Article  PubMed  CAS  Google Scholar 

  100. van Moffaert M, de Wilde J, Vereecken A, et al. Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression. Int Clin Psychopharmacol 1995; 10(1): 3–9

    Article  PubMed  Google Scholar 

  101. Thase ME, Clayton AH, Haight BR, et al. A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability. J Clin Psychopharmacol 2006; 26(5): 482–8

    Article  PubMed  CAS  Google Scholar 

  102. Martinez C, Rietbrock S, Wise L, et al. Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. BMJ 2005; 330(7488): 389

    Article  PubMed  CAS  Google Scholar 

  103. Didham RC, McConnell DW, Blair HJ, et al. Suicide and selfharm following prescription of SSRIs and other antidepressants: confounding by indication. Br J Clin Pharmacol 2005; 60(5): 519–25

    Article  PubMed  Google Scholar 

  104. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA 2004; 292(3): 338–43

    Article  PubMed  CAS  Google Scholar 

  105. Jick SS, Dean AD, Jick H. Antidepressants and suicide. BMJ 1995; 310(6974): 215–8

    Article  PubMed  CAS  Google Scholar 

  106. Khan A, Khan S, Kolts R, et al. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am J Psychiatry 2003; 160(4): 790–2

    Article  PubMed  Google Scholar 

  107. Rubino A, Roskell N, Tennis P, et al. Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study [abstract]. BMJ 2007; 334(7587): 242

    Article  PubMed  CAS  Google Scholar 

  108. Montejo AL, Llorca G, Izquierdo JA, et al. Incidence of sexual dysfunction associated with antidepressant agents: a prospec-tive multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunc-tion. J Clin Psychiatry 2001; 62 Suppl. 3: 10–21

    PubMed  CAS  Google Scholar 

  109. Clayton AH, Pradko JF, Croft HA, et al. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002; 63(4): 357–66

    Article  PubMed  Google Scholar 

  110. Johnston JA, Lineberry CG, Ascher JA, et al. A 102-center prospective study of seizure in association with bupropion. J Clin Psychiatry 1991; 52(11): 450–6

    PubMed  CAS  Google Scholar 

  111. Dunner DL, Zisook S, Billow AA, et al. A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J Clin Psychiatry 1998; 59(7): 366–73

    Article  PubMed  CAS  Google Scholar 

  112. Whyte IM, Dawson AH, Buckley NA. Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM 2003; 96(5): 369–74

    Article  PubMed  CAS  Google Scholar 

  113. Buckley NA, McManus PR. Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data. BMJ 2002; 325(7376): 1332–3

    Article  PubMed  Google Scholar 

  114. Thapa PB, Gideon P, Cost TW, et al. Antidepressants and the risk of falls among nursing home residents. N Engl J Med 1998; 339(13): 875–82

    Article  PubMed  CAS  Google Scholar 

  115. Mackay FJ, Dunn NR, Wilton LV, et al. A comparison of fluvoxamine, fluoxetine, sertraline and paroxetine examined by observational cohort studies. Pharmacoepidemiol Drug Saf 1997; 6(4): 235–46

    Article  PubMed  CAS  Google Scholar 

  116. Mackay FR, Dunn NR, Martin RM, et al. Newer antidepressants: a comparison of tolerability in general practice. Br J Gen Pract 1999; 49(448): 892–6

    PubMed  CAS  Google Scholar 

  117. Meijer WE, Heerdink ER, van Eijk JT, et al. Adverse events in users of sertraline: results from an observational study in psychiatric practice in The Netherlands. Pharmacoepidemiol Drug Saf 2002; 11(8): 655–62

    Article  PubMed  CAS  Google Scholar 

  118. Thase ME, Tran PV, Wiltse C, et al. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J Clin Psychopharmacol 2005; 25(2): 132–40

    Article  PubMed  CAS  Google Scholar 

  119. Kennedy SH, Eisfeld BS, Dickens SE, et al. Antidepressantinduced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 2000; 61(4): 276–81

    Article  PubMed  CAS  Google Scholar 

  120. Landen M, Hogberg P, Thase ME. Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine. J Clin Psychiatry 2005; 66(1): 100–6

    Article  PubMed  CAS  Google Scholar 

  121. Philipp M, Tiller JW, Baier D, et al. Comparison of moclobemide with selective serotonin reuptake inhibitors (SSRIs) on sexual function in depressed adults. The Australian and German Study Groups. Eur Neuropsychopharmacol 2000; 10(5): 305–14

    Article  CAS  Google Scholar 

  122. Kirby D, Harrigan S, Ames D. Hyponatraemia in elderly psychiatric patients treated with Selective Serotonin Reuptake Inhibitors and venlafaxine: a retrospective controlled study in an inpatient unit. Int J Geriatr Psychiatry 2002; 17(3): 231–7

    Article  PubMed  Google Scholar 

  123. Mackay FJ, Dunn NR, Mann RD. Antidepressants and the serotonin syndrome in general practice. Br J Gen Pract 1999; 49(448): 871–4

    PubMed  CAS  Google Scholar 

  124. Lindstrom E, Lewander T, Malm U, et al. Patient-rated versus clinician-rated side effects of drug treatment in schizophrenia. Clinical validation of a self-rating version of the UKU Side Effect Rating Scale (UKU-SERS-Pat). Nord J Psychiatry 2001; 55 (Suppl. 44): 5–69

    PubMed  Google Scholar 

  125. US Food and Drug Administration. Guideline for industry. Clinical safety data management: definitions and standards for expedited reporting [online]. Available from URL: http://www.fda.gov/cder/guidance/iche2a.pdf [Accessed 2008 Feb 18]

  126. Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. BMJ 1995; 310(6992): 1433–8

    Article  PubMed  CAS  Google Scholar 

  127. Delgado PL, Brannan SK, Mallinckrodt CH, et al. Sexual functioning assessed in 4 double-blind placeboand paroxetinecontrolled trials of duloxetine for major depressive disorder. J Clin Psychiatry 2005; 66(6): 686–92

    Article  PubMed  Google Scholar 

  128. Liu BA, Mittmann N, Knowles SR, et al. Hyponatremia and the syndrome of innappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports. CMAJ 1996; 155(5): 519–27

    PubMed  CAS  Google Scholar 

  129. Stewart DE. Hepatic adverse reactions associated with nefazodone. Can J Psychiatry 2002; 47(4): 375–7

    PubMed  Google Scholar 

  130. Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome: presentation of 2 cases and review of the literature. Medicine (Baltimore) 2000; 79(4): 201–9

    Article  CAS  Google Scholar 

  131. Montgomery SA, Henry J, McDonald G, et al. Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol 1994; 9(1): 47–53

    Article  PubMed  CAS  Google Scholar 

  132. Egger M, Smith GD, Altman DG. Systematic reviews in health care. 2nd ed. London: BMJ Publishing Group, 2001

    Book  Google Scholar 

  133. Clerc GE, Ruimy P, Verdeau-Palles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group. Int Clin Psychopharmacol 1994; 9(3): 139–43

    Article  CAS  Google Scholar 

  134. Berkman ND, Bulik CM, Brownley KA, et al. Management of eating disorders, Evidence Report/Technology Assessment No. 135. AHRQ Publication No. 06-E 010. Rockville (MD): Agency for Healthcare Research and Quality, 2006 Apr

    Google Scholar 

  135. Anonymous. Depressing research. Lancet 2004; 363(9418): 1335

    Article  Google Scholar 

  136. Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med 2002; 21(16): 2313–24

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Gerald Gartlehner.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gartlehner, G., Thieda, P., Hansen, R.A. et al. Comparative Risk for Harms of Second Generation Antidepressants. Drug-Safety 31, 851–865 (2008). https://doi.org/10.2165/00002018-200831100-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200831100-00004

Keywords

Navigation